46 results on '"Michael, Dickinson"'
Search Results
2. Embedding rehabilitation into cancer care continuum: an implementation study
- Author
-
Fary Khan, Bhasker Amatya, Alaeldin Elmalik, Krystal Song, Demi Diaz, and Michael Dickinson
- Subjects
cancer ,rehabilitation ,implementation ,barriers ,facilitators ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Objectives: To implement and evaluate a rehabilitation-inclusive service delivery model at a tertiary cancer hospital. Methods: The “Rehab-Toolkit”, a structured assessment tool comprising validated functional measures, was introduced in an inpatient cancer service. Consecutive inpatients were enrolled, and a Reach, Effectiveness, Adoption, Implementation, and Maintenance framework guided the analysis of barriers and facilitators for subacute care at clinic and system levels. Results: The implementation of the Rehab-Toolkit was incorporated into routine inpatient care. Major pre-implementation barriers included: absence of routine standardized functional assessment tools, limited coordination amongst acute and subacute care providers, low awareness of rehabilitation medicine amongst patients and professionals, and insufficient engagement of subacute care with interdisciplinary stakeholders in clinical decision-making. Following the intervention, there was a notable increase in awareness and the contributory role of subacute rehabilitation services, rehabilitation “needs” assessment, and referral pathways. Recommendations for process change included: development of clinical pathways, establishment of subacute referral systems and discharge coordinator roles, inclusion of subacute rehabilitation services in acute interdisciplinary team meetings, enhanced staff education and knowledge. Conclusion: Integration of rehabilitation services into cancer care can proactively manage functional morbidity. While the implementation process proved feasible and effective, robust process evalu-ation and longer term follow-up are necessary for sustained success.
- Published
- 2024
- Full Text
- View/download PDF
3. Healthcare Internet of Things system implementations for COVID-19 prevention
- Author
-
Jichao Leng, Zihuai Lin, Soojeong Yoo, Gabriella Scandurra, Michael Dickinson, Branka Vucetic, and Audrey P. Wang
- Subjects
healthcare (MeSH) ,internet of things (IoT) ,COVID-19 ,digital health (eHealth) ,system implementation ,Communication. Mass media ,P87-96 - Abstract
BackgroundIn response to the widespread transmission of COVID-19 in Australia, healthcare facilities implemented stringent infection control measures, and mandatory and manual screening procedures were introduced to ensure the safety of patients and healthcare staff. However, these necessary measures resulted in imbalances within the healthcare system, a shortage of front-line workers and impacts on patient experience and wait times. The prioritization of infection control measures shifted resources away from routine care, causing delays in accessing necessary healthcare services.Methods and FindingsTo address these challenges, we developed and implemented an Internet of Things (IoT) Smart Screening eGate solution in partnership with a large metropolitan children’s hospital in Australia. This solution integrated a contactless health self-service web app, thermal camera, and physical barrier to automate the COVID-19 health screening and data recording process. During the 3-month pilot period, we deployed the eGate at multiple entrances to the hospital, and monitored the number of users of the system in different periods. We also used a framework of formative evaluation to classify user design challenges within limited resources and improved the design of the eGate to enhance its effectiveness. Our findings show that the IoT eGate solution improved the efficiency of the screening process and reduced the workload and exposure risks of front-line staff and anyone who required access to the hospital. By automating the screening process, we reduced the need for manual screening and minimized contact between individuals, thus reducing the risk of potentially infected.ConclusionIn conclusion, our pilot study demonstrated the potential of IoT technologies in improving the efficiency and safety of medical facilities during pandemics and provided a series of recommendations for the translation of IoT technologies for medical facilities, including the importance of co-design and collaboration with stakeholders, user-centered design, and ongoing monitoring and evaluation.
- Published
- 2024
- Full Text
- View/download PDF
4. Neuropsychological outcomes of patients with haematological malignancies undergoing chimeric antigen receptor T-cell therapy: protocol for a prospective study
- Author
-
Tomas Kalincik, Charles B Malpas, Michael Dickinson, Izanne Roos, Stefanie Roberts, Samantha M Loi, Mark Dowling, Carmela Sales, Fiore D’Aprano, Valeriya Kuznetsova, Harsh Oza, Hannah Rosenfeld, Samantha van der Linde, Simon J Harrison, and Mary Ann Anderson
- Subjects
Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Introduction Immune effector cell-associated neurotoxicity syndrome (ICANS) is a common side-effect of chimeric antigen receptor T-cell (CAR-T) therapy, with symptoms ranging from mild to occasionally life-threatening. The neurological, cognitive, psychiatric and psychosocial sequelae of ICANS are diverse and not well defined, posing a challenge for diagnosis and management. The recovery trajectory of the syndrome is uncertain. Patients are rarely examined in this population pretherapy, adding a layer of complexity to specifying symptoms pertinent solely to CAR-T treatment. We present a protocol of a prospective longitudinal research study of adult patients in a single Australian haematology service undergoing CAR-T therapy. The study will describe neurocognitive features specific to ICANS, characterise the underlying syndrome, capture recovery, identify predictors of differential postinfusion outcomes and determine a set of cognitive instruments necessary to monitor patients acutely.Methods and analysis This is a prospective longitudinal study that comprises neuropsychological and neurological examinations occurring prior to CAR-T, during the acute post-treatment period, 28 days, 6 months and 12 months post infusion. Data will be sourced from objective psychometric measures, clinical examinations, self-report questionnaires of psychopathology and accounts of subjective cognitive complaint.Ethics and dissemination This study aims to guide diagnosis, management and monitoring of neurocognitive features of CAR-T cell therapy. Results of this study will be disseminated through publication in peer-reviewed journals and presentations at scientific conferences. All procedures involving human subjects/patients were approved by the Peter MacCallum Cancer Centre Human Research Ethics Committee (21/145).
- Published
- 2024
- Full Text
- View/download PDF
5. Web-based cognitive rehabilitation intervention for cancer-related cognitive impairment following chemotherapy for aggressive lymphoma: protocol for a randomised pilot trial
- Author
-
Victoria White, Patricia M Livingston, Meinir Krishnasamy, Anna Ugalde, Haryana Dhillon, Karla Gough, Priscilla Gates, Janette L Vardy, Karen Caeyenberghs, Michael Dickinson, Heather J Green, and Jade Guarnera
- Subjects
Medicine - Abstract
Introduction Cancer-related cognitive impairment is common among people diagnosed with and treated for cancer. This can be a distressing and disabling side effect for impacted individuals. Interventions to mitigate cognitive dysfunction are available, but, to date, most have been trialled in samples that are largely or exclusively composed of people with solid tumours. Intervention strategies to support cognitive functioning are needed, but there is a paucity of research in this area. The main aim of this study is to test the feasibility and acceptability of methods and procedures intended for use in a definitive trial of a web-based cognitive rehabilitation programme, Responding to Cognitive Concerns (eReCog), in people who have received chemotherapy for aggressive lymphoma.Methods and analysis The proposed study is a single-site, parallel-group, pilot randomised controlled trial, with one baseline and one follow-up (or postintervention) assessment. 38 people from the target population with low perceived cognitive function based on the Cognitive Change Screen will be recruited from a specialist cancer centre between July 2023 and June 2024. After baseline assessment, participants will be randomised one-to-one to receive usual care only (a factsheet about changes in memory and thinking for people with cancer) or eReCog plus usual care. The 4-week eReCog intervention consists of four online modules offering psychoeducation on cognitive impairment associated with cancer and its treatment, skills training for improving memory, and attention and relaxation training. Study outcomes will include the feasibility of recruitment and retention at follow-up assessment (primary outcomes), as well as adherence to, usability of and intrinsic motivation to engage with eReCog, and compliance with study measures. The potential efficacy of eReCog will also be evaluated.Ethics and dissemination Ethical approval was granted by the Peter MacCallum Cancer Centre Human Research Ethics Committee in Victoria, Australia (HREC/97384/PMCC). Study findings will be disseminated via peer-reviewed publications and conference presentations.Trial registration number Australian New Zealand Clinical Trials Registry, ACTRN12623000705684.
- Published
- 2024
- Full Text
- View/download PDF
6. Next‐generation sequencing of baseline genetic mutations and outcomes of eltrombopag and azacitidine therapy in patients with myelodysplastic syndromes and thrombocytopenia: Data from the SUPPORT clinical trial
- Author
-
Pedro Marques Ramos, Jeea Choi, Catarina D. Campbell, Ying A. Wang, Celine Pallaud, Michael Dickinson, Amit Verma, Moshe Mittelman, Uwe Platzbecker, Honar Cherif, and Pierre Fenaux
- Subjects
azacitidine ,myelodysplastic syndromes ,NGS ,thrombocytopenia ,thrombopoietin receptor agonist ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Abstract Eltrombopag has been previously shown to be effective in reversing azacitidine‐mediated thrombocytopenia. This was further investigated in the SUPPORT trial, a phase III study assessing the efficacy/safety of eltrombopag plus azacitidine in patients with intermediate‐ to high‐risk myelodysplastic syndromes and thrombocytopenia. The results did not support a clinical benefit for the addition of eltrombopag to azacitidine. We investigated if the somatic mutational profiles in the patient cohort were associated with treatment outcomes. Based on the available data, we observed no imbalance in the mutational profiles between treatment arms or a clear association between identified somatic mutations and clinical outcomes.
- Published
- 2023
- Full Text
- View/download PDF
7. Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study
- Author
-
Allison Barraclough, Shivam Agrawal, Dipti Talaulikar, Geoffrey Chong, Edward Yoo, Chan Y. Cheah, Nunzio Franco, Bianca Nguyen, Howard Mutsando, Fatima Tahir, Judith Trotman, Jing Huang, Colm Keane, Mitchel Lincoln, Tara Cochrane, Anna M. Johnston, Michael Dickinson, Stephen Opat, Zoe K. McQuilten, Erica M. Wood, Gayathri St George, and Eliza A. Hawkes
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Follicular Lymphoma (FL) treatment initiation is largely determined by tumor burden and symptoms. In the pre-rituximab era, the Group d’Etude des Lymphomes Folliculaires (GELF) developed widely adopted criteria to identify high tumor burden FL patients to harmonize clinical trial populations. The utilization of GELF criteria (GELFc) in routine therapeutic decision-making is poorly described. This multicenter retrospective study evaluated patterns of GELFc at presentation and GELFc utilization in therapeutic decision-making in newly diagnosed, advanced stage rituximab-era FL. Associations between GELFc, treatment given, and patient survival were analyzed in 300 eligible cases identified between 2002-2019. 163 (54%) had ≥1 GELFc at diagnosis. The presence or cumulative number of GELFc did not predict PFS in patients undergoing watch-and-wait (WW) or those receiving systemic treatment. Of interest, in patients with ≥1 GELFc, 16/163 (10%) underwent initial watch-and-wait (comprising 22% of the watchand- wait cohort). In those receiving systemic therapy +/- radiotherapy, 74/215 (34%) met no GELFc. Our data suggest clinicians are using adjunctive measures to make decisions regarding treatment initiation in a significant proportion of patients. By restricting FL clinical trial eligibility only to those meeting GELFc, reported outcomes may not be applicable to a significant proportion of patients treated in routine care settings.
- Published
- 2024
- Full Text
- View/download PDF
8. Short- and long-term effects of an electronic medication management system on paediatric prescribing errors
- Author
-
Johanna I. Westbrook, Ling Li, Magdalena Z. Raban, Virginia Mumford, Tim Badgery-Parker, Peter Gates, Erin Fitzpatrick, Alison Merchant, Amanda Woods, Melissa Baysari, Cheryl McCullagh, Ric Day, Madlen Gazarian, Michael Dickinson, Karla Seaman, Lucciano Dalla-Pozza, Geoffrey Ambler, Peter Barclay, Alan Gardo, Tracey O’Brien, Draga Barbaric, and Les White
- Subjects
Computer applications to medicine. Medical informatics ,R858-859.7 - Abstract
Abstract Electronic medication management (eMM) systems are designed to improve safety, but there is little evidence of their effectiveness in paediatrics. This study assesses the short-term (first 70 days of eMM use) and long-term (one-year) effectiveness of an eMM system to reduce prescribing errors, and their potential and actual harm. We use a stepped-wedge cluster randomised controlled trial (SWCRCT) at a paediatric referral hospital, with eight clusters randomised for eMM implementation. We assess long-term effects from an additional random sample of medication orders one-year post-eMM. In the SWCRCT, errors that are potential adverse drug events (ADEs) are assessed for actual harm. The study comprises 35,260 medication orders for 4821 patients. Results show no significant change in overall prescribing error rates in the first 70 days of eMM use (incident rate ratio [IRR] 1.05 [95%CI 0.92–1.21], but a 62% increase (IRR 1.62 [95%CI 1.28–2.04]) in potential ADEs suggesting immediate risks to safety. One-year post-eMM, errors decline by 36% (IRR 0.64 [95%CI 0.56–0.72]) and high-risk medication errors decrease by 33% (IRR 0.67 [95%CI 0.51–0.88]) compared to pre-eMM. In all periods, dose error rates are more than double that of other error types. Few errors are associated with actual harm, but 71% [95%CI 50–86%] of patients with harm experienced a dose error. In the short-term, eMM implementation shows no improvement in error rates, and an increase in some errors. A year after eMM error rates significantly decline suggesting long-term benefits. eMM optimisation should focus on reducing dose errors due to their high frequency and capacity to cause harm.
- Published
- 2022
- Full Text
- View/download PDF
9. S261: FIRST IN HUMAN DATA OF NKX019, AN ALLOGENEIC CAR NK FOR THE TREATMENT OF RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES
- Author
-
Michael Dickinson, Nada Hamad, Christian Bryant, Nishi Kothari, Paulius Ojeras, Anmol Vohra, Ming Lin, Mira Tohme, James Trager, David Shook, Glen Kennedy, Michael Tees, and Brian T. Hill
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2023
- Full Text
- View/download PDF
10. P1066: PEMBROLIZUMAB MONOTHERAPY AS A FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD INELIGIBLE PATIENTS, DOES NOT PRECLUDE SUBSEQUENT THERAPY, AND PROVIDES ADEQUATE SURVIVAL.
- Author
-
Michael Dickinson, Leanne Berkahn, Judith Trotman, Jason Butler, Paul Neeson, Matthias Bressel, and Adrian Minson
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2023
- Full Text
- View/download PDF
11. P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY
- Author
-
Martin Hutchings, Carmelo Carlo-Stella, Franck Morschhauser, Michael Dickinson, Emmanuel Bachy, Guillaume Cartron, Cyrus Khan, Monica Tani, Joaquín Martinez-Lopez, Nancy L. Bartlett, Antonio Salar, Joshua Brody, Sirpa Leppa, Pauline Baumlin, Linda Lundberg, James Relf, Yuying Xie, Alessia Bottos, Kathryn Humphrey, and Lorenzo Falchi
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2023
- Full Text
- View/download PDF
12. P1117: GLOFITAMAB PLUS R-CHOP OR POLATUZUMAB VEDOTIN-R-CHP IS DELIVERABLE AND YIELDS HIGH OVERALL RESPONSE IN PATIENTS
- Author
-
Adrian Minson, Emma Verner, Pratyush Giri, Shu Min Wong, Sumita Ratnasingam, Jason Butler, Wojciech Janowski, Matthew Ku, Chan Cheah, Mark Hertzberg, Kirsten Herbert, Nada Hamad, Costas Yannakou, Paul Neeson, Javad Saghebi, Piers Blombery, Molly Robertson, Lei Shong Lau, Jing Xie, John Seymour, and Michael Dickinson
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2023
- Full Text
- View/download PDF
13. P1156: IN THE ABSENCE OF SYMPTOMS OR CEREBROSPINAL FLUID INVOLVEMENT, MRI STAGING OF THE CENTRAL NERVOUS SYSTEM (CNS) IN PATIENTS WITH SYSTEMIC DIFFUSE LARGE B-CELL LYMPHOMA RARELY DETECTS DISEASE
- Author
-
Manu Juneja, Rory Bennett, Mary Ann Anderson, Adrian Minson, Max Wolf, Kirsten Herbert, Graham J Lieschke, Andrew Roberts, Kylie Mason, John Seymour, and Michael Dickinson
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2023
- Full Text
- View/download PDF
14. PB2319: ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA
- Author
-
Jason Westin, Caron Jacobson, Julio C Chavez, Anna Sureda, Franck Morschhauser, Bertram Glass, Michael Dickinson, Andrew J. Davies, Ian W. Flinn, David Maloney, Martine Chamuleau, Michael Tees, Allen Xue, Shilpa Shahani, Olga Nikolajeva, Janet Kang, Aida Kaplan, Marco Schupp, Harry Miao, and Elizabeth Shima Rich
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2023
- Full Text
- View/download PDF
15. The soluble receptor for advanced glycation end products is potentially predictive of pulmonary arterial hypertension in systemic sclerosis
- Author
-
Isabella M. Atzeni, Yehya Al-Adwi, Berber Doornbos-van der Meer, Caroline Roozendaal, Alja Stel, Harry van Goor, C. Tji Gan, Michael Dickinson, Wim Timens, Andries J. Smit, Johanna Westra, and Douwe J. Mulder
- Subjects
PAH ,sRAGE ,predictability ,SSc ,scleroderma ,ILD ,Immunologic diseases. Allergy ,RC581-607 - Abstract
IntroductionPulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are the leading causes of death in systemic sclerosis (SSc). Until now, no prospective biomarker to predict new onset of SSc-ILD or SSc-PAH in patients with SSc has reached clinical application. In homeostasis, the receptor for advanced glycation end products (RAGE) is expressed in lung tissue and involved in cell-matrix adhesion, proliferation and migration of alveolar epithelial cells, and remodeling of the pulmonary vasculature. Several studies have shown that sRAGE levels in serum and pulmonary tissue vary according to the type of lung-related complication. Therefore, we investigated levels of soluble RAGE (sRAGE) and its ligand high mobility group box 1 (HMGB1) in SSc and their abilities to predict SSc-related pulmonary complications.MethodsOne hundred eighty-eight SSc patients were followed retrospectively for the development of ILD, PAH, and mortality for 8 years. Levels of sRAGE and HMGB1 were measured in serum by ELISA. Kaplan-Meier survival curves were performed to predict lung events and mortality and event rates were compared with a log-rank test. Multiple linear regression analysis was performed to examine the association between sRAGE and important clinical determinants.ResultsAt baseline, levels of sRAGE were significantly higher in SSc-PAH-patients (median 4099.0 pg/ml [936.3-6365.3], p = 0.011) and lower in SSc-ILD-patients (735.0 pg/ml [IQR 525.5-1988.5], p = 0.001) compared to SSc patients without pulmonary involvement (1444.5 pg/ml [966.8-2276.0]). Levels of HMGB1 were not different between groups. After adjusting for age, gender, ILD, chronic obstructive pulmonary disease, anti-centromere antibodies, the presence of puffy fingers or sclerodactyly, use of immunosuppression, antifibrotic therapy, or glucocorticoids, and use of vasodilators, higher sRAGE levels remained independently associated with PAH. After a median follow-up of 50 months (25-81) of patients without pulmonary involvement, baseline sRAGE levels in the highest quartile were predictive of development of PAH (log-rank p = 0.01) and of PAH-related mortality (p = 0.001).ConclusionsHigh systemic sRAGE at baseline might be used as a prospective biomarker for patients with SSc at high risk to develop new onset of PAH. Moreover, high sRAGE levels could predict lower survival rates due to PAH in patients with SSc.
- Published
- 2023
- Full Text
- View/download PDF
16. Factors associated with long-term functional and psychosocial outcomes in patients with non-Hodgkin lymphoma
- Author
-
Bhasker Amatya, Michael Dickinson, and Fary Khan
- Subjects
Non-Hodgkin lymphoma ,rehabilitation ,impairment ,function ,quality of life ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Objective: To assess the long-term functional, psychosocial and participation outcomes in an Australian cohort of non-Hodgkin lymphoma (NHL) survivors. Methods: A cross-sectional sample of adult NHL survivors at the Peter MacCallum Cancer Centre (between 2015 and 2020), participated by completing validated questionnaires. A series of analyses described their current level of function, psychosocial well-being, and participation. Results: Of 129 participants (mean (M) ± standard deviation (SD) age: 62.5 ± 8.8 years), the majority (58%) had aggressive NHL and grade III–IV (72%), with time since diagnosis of 4.6 ± 1.2 years. Participants reported ongoing issues after completion of treatment: fatigue (63%), bladder dysfunction (61%), cognitive impairment (53%), and NHL-related pain (46%). Most made good functional recovery (M ± SD) (Functional Independent Measure-Motor: 79.5 ± 8.2), reported minimal change in their negative emotional states, and NHL-specific quality of life (QoL) (Functional Assessment of Cancer Therapy–Lymphoma: 133.5 ± 22.1). Participants were “well” adjusted to community living (Community Integration Measure: 42.2 ± 7.4) and satisfied with their current life (Satisfaction with Life Scale: 26.3 ± 6.0). Factors significantly associated with the poorer current level of function were: age at diagnosis < 60 years, time since NHL diagnosis > 4.5 years, and aggressive NHL type. Conclusion: Despite good functional recovery and adjustment in the community, NHL survivors report the presence of ongoing residual impairments and cognitive issues, which requires long-term rehabilitation-inclusive management. LAY ABSTRACT This cross-sectional study evaluated functional and psychosocial outcomes in non-Hodgkin lymphoma (NHL) survivors. Most patients made a good functional recovery and reported minimal change in their negative emotional states and quality of life after they were discharged. Patients reported satisfaction with their current life and were “well” adjusted to community living after NHL treatment. However, many reported ongoing issues, specifically fatigue, bladder dysfunction, cognitive impairment, and NHL-related pain. Those below 60 years of age when diagnosed, with time since NHL of over 4.5 years, and with aggressive and advanced NHL grades were associated with a poorer current level of function. These findings suggest that, despite patients’ potential adjustment to disability over time (response-shift phenomenon), many patients with NHL need long-term rehabilitation-inclusive management of ongoing disability and psychosocial issues in the community post-discharge.
- Published
- 2023
- Full Text
- View/download PDF
17. Providing optimal care for active youth in Canada
- Author
-
Laura Purcell, Sarah Campos, Michael Dickinson, Graham Thompson, and Tatiana Jevremovic
- Subjects
Education (General) ,L7-991 ,Medicine (General) ,R5-920 - Abstract
Sports are important activities for youth, with millions of children and adolescents participating in organized sports and recreational activities every year. Sports participation has many benefits but can also cause injuries, accounting for two-thirds of all injuries in Canadian adolescents and resulting in hundreds of thousands of medical visits annually. Despite the frequency of sports-related injuries in youth, many practising pediatricians are not comfortable managing these issues, citing a lack of teaching and clinical exposure during training. Many studies have found deficits in musculoskeletal (MSK) and sport and exercise medicine (SEM) training in residency programs in North America, including Canadian pediatric residency programs. To address this learning gap, Canadian pediatric residency programs should incorporate more MSK/SEM training and clinical exposure to these issues. A standardized national curriculum in MSK/SEM will help ensure that community pediatricians practicing in Canada are adequately prepared to care for active youth.
- Published
- 2022
- Full Text
- View/download PDF
18. Ventricular Septal Rupture in 2 Patients Presenting Late after Myocardial Infarction during the COVID-19 Pandemic
- Author
-
Malav Parikh, MD, Meredith Busman, MD, Michael Dickinson, MD, David Wohns, MD, and Ryan D. Madder, MD
- Subjects
mechanical complication ,myocardial infarction ,STEMI ,ventricular septal defect ,ventricular septal rupture ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Ventricular septal rupture (VSR) following myocardial infarction is rare in the reperfusion era. The decrease in patients presenting with myocardial infarction during the coronavirus-2019 (COVID-19) pandemic could result in more frequent VSR. This report describes two patients with VSR presenting late after myocardial infarction and treated at a single institution. (Level of Difficulty: Beginner.)
- Published
- 2020
- Full Text
- View/download PDF
19. Rehabilitation in patients with lymphoma: An overview of Systematic Reviews
- Author
-
Bhasker Amatya, Fary Khan, Thomas E. Lew, and Michael Dickinson
- Subjects
lymphoma ,rehabilitation ,systematic review ,critical appraisal. ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Objective: To evaluate existing evidence from published systematic reviews for the effectiveness of rehabilitation interventions in patients with lymphoma. Data sources: A comprehensive literature search was conducted using medical/health science databases up to 1 October 2020. Bibliographies of pertinent articles, journals and grey literature were searched. Data extraction and synthesis: Two reviewers independently selected and reviewed potential reviews for methodological quality and graded the quality of evidence for outcomes using validated tools. Any discrepancies were resolved by final group consensus. Results: Twelve systematic reviews (n = 101 studies, 87,132 patients with lymphoma) evaluated 3 broad categories of rehabilitation interventions (physical modalities, nutrition and complementary medicine). Most reviews were of moderate-to-low methodological quality. The findings suggest: moderate-quality evidence for exercise programmes for improved fatigue and sleep disturbance; low-quality evidence for exercise therapy alone and qigong/tai chi for improved symptoms and overall quality of life, and an inverse association between sunlight/ultraviolet radiation exposure and incidence of non-Hodgkin’s lymphoma; and very low-quality evidence for beneficial effects of yoga for sleep disturbances. Association between physical activity and lymphoma risk is indistinct. Conclusion: Despite a range of rehabilitation modalities used for patients with lymphoma, high-quality evidence for many is sparse. Beneficial effects of exercise programmes were noted for fatigue, psychological symptoms and quality of life. More research with robust study design is required to determine the effective rehabilitation approaches.
- Published
- 2021
- Full Text
- View/download PDF
20. My Health Memory - A lifetime medical record in the hands of patients and carers
- Author
-
Cheryl Mccullagh, Lisa Altman, Michael Dickinson, and Ben Williams
- Subjects
emr ,app ,technology ,integration ,Medicine (General) ,R5-920 - Abstract
Sydney Children’s Hospitals Network (SCHN) is the largest network of hospitals and services for children in Australia. It is a public service of NSW (New South Wales) Health, part of the NSW Government. The NSW geographic area serviced is 800,628 square km, with a population of 7,861,100 people, but children come from across Australia for the expert care SCHN provides. SCHN cares for 151,000 children every year, with over 50,000 inpatient admissions and over 1.1m outpatient encounters. More than 65% of these presentations consist of patients who have an established relationship with SCHN due to the complex/chronic nature of their diagnosis(s). SCHN wanted to connect with their outpatients, to inform/support changing care needs, to improve patients’ understanding of their conditions and to connect information across providers. All patients have providers locally outside the network, so SCHN wanted to support the patient as the conduit of their information, ultimately improving the care experience and health outcomes. SCHN had a vision of giving patients a digital record they could interact with meaningfully, centered around them. This digital vision would address several care delivery challenges: inefficient communication missed appointments managing changing conditions and medications lack of a shared record The digital vision became a co-design project with SCHN’s consumers, named the “Memory” project. The vision became reality in May 2017 with the successful trial of the “My Health Memory” (MHM) smartphone application. The first iteration of MHM allowed patients and carers to: Efficiently manage appointments and minimise care delays: receive new and updated appointments (including telehealth links straight to device) automatically from the EHR to their app request reschedules from their app receive appointment reminders, ensuring they come to appointments, are ready for care, and can find their way with digital wayfinding instructions staff can asynchronously review and reschedule requests via a request list and rebook Exchange clinical data to support care: access discharge summaries, care plans and reconciled medication lists from their app. push education to the app Communicate securely: clinical staff can securely message patients/carers from their workflow, and patients/carers can respond from their app. communications are automatically saved as a progress note in the EHR, eliminating manual documentation trial group implementation was a success resulting in a hospital wide implementation March 2018. Metrics achieved include: 80% of eligible patients registered (from trial group) Outpatient clinic No Show rates decreased by 74%. 8,748 messages sent between MHM and the EHR resulting in 30% fewer outpatient calls to nursing staff Reduction in secondary sources of truth for patient communication, reducing iatrogenic risk. 94.9% of app users have rated MHM as being useful in the care of their child. over 7,000 EHR documents shared to the app Over 6,000 activated users (October 2018) The 6 month MHM app roadmap includes; patient/carer uploaded documents and document sharing. Surveys with EHR integration & integration to Australia’s My Health Record. Sydney University have commenced a study On the MHM app titled Leveraging e-Applications for Patients (and families)
- Published
- 2019
- Full Text
- View/download PDF
21. Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS
- Author
-
Gareth P. Gregory, Michael Dickinson, Costas K. Yannakou, Jonathan Wong, Piers Blombery, Greg Corboy, Lev Kats, Tim M.E. Crozier, Beena Kumar, H. Miles Prince, Stephen S. Opat, and Jake Shortt
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2019
- Full Text
- View/download PDF
22. From waste to food: Optimising the breakdown of oil palm waste to provide substrate for insects farmed as animal feed.
- Author
-
Elizabeth Dickinson, Mark Harrison, Marc Parker, Michael Dickinson, James Donarski, Adrian Charlton, Rosie Nolan, Aida Rafat, Florence Gschwend, Jason Hallett, Maureen Wakefield, and Julie Wilson
- Subjects
Medicine ,Science - Abstract
Waste biomass from the palm oil industry is currently burned as a means of disposal and solutions are required to reduce the environmental impact. Whilst some waste biomass can be recycled to provide green energy such as biogas, this investigation aimed to optimise experimental conditions for recycling palm waste into substrate for insects, farmed as a sustainable high-protein animal feed. NMR spectroscopy and LC-HRMS were used to analyse the composition of palm empty fruit bunches (EFB) under experimental conditions optimised to produce nutritious substrate rather than biogas. Statistical pattern recognition techniques were used to investigate differences in composition for various combinations of pre-processing and anaerobic digestion (AD) methods. Pre-processing methods included steaming, pressure cooking, composting, microwaving, and breaking down the EFB using ionic liquids. AD conditions which were modified in combination with pre-processing methods were ratios of EFB:digestate and pH. Results show that the selection of pre-processing method affects the breakdown of the palm waste and subsequently the substrate composition and biogas production. Although large-scale insect feeding trials will be required to determine nutritional content, we found that conditions can be optimised to recycle palm waste for the production of substrate for insect rearing. Pre-processing EFB using ionic liquid before AD at pH6 with a 2:1 digestate:EFB ratio were found to be the best combination of experimental conditions.
- Published
- 2019
- Full Text
- View/download PDF
23. NMR Metabolomics Defining Genetic Variation in Pea Seed Metabolites
- Author
-
Noel Ellis, Chie Hattori, Jitender Cheema, James Donarski, Adrian Charlton, Michael Dickinson, Giampaolo Venditti, Péter Kaló, Zoltán Szabó, György B. Kiss, and Claire Domoney
- Subjects
genetic map ,genetic variation ,pea ,seed ,metabolite ,nuclear magnetic resonance ,Plant culture ,SB1-1110 - Abstract
Nuclear magnetic resonance (NMR) spectroscopy profiling was used to provide an unbiased assessment of changes to the metabolite composition of seeds and to define genetic variation for a range of pea seed metabolites. Mature seeds from recombinant inbred lines, derived from three mapping populations for which there is substantial genetic marker linkage information, were grown in two environments/years and analyzed by non-targeted NMR. Adaptive binning of the NMR metabolite data, followed by analysis of quantitative variation among lines for individual bins, identified the main genomic regions determining this metabolic variability and the variability for selected compounds was investigated. Analysis by t-tests identified a set of bins with highly significant associations to genetic map regions, based on probability (p) values that were appreciably lower than those determined for randomized data. The correlation between bins showing high mean absolute deviation and those showing low p-values for marker association provided an indication of the extent to which the genetics of bin variation might be explained by one or a few loci. Variation in compounds related to aromatic amino acids, branched-chain amino acids, sucrose-derived metabolites, secondary metabolites and some unidentified compounds was associated with one or more genetic loci. The combined analysis shows that there are multiple loci throughout the genome that together impact on the abundance of many compounds through a network of interactions, where individual loci may affect more than one compound and vice versa. This work therefore provides a framework for the genetic analysis of the seed metabolome, and the use of genetic marker data in the breeding and selection of seeds for specific seed quality traits and compounds that have high commercial value.
- Published
- 2018
- Full Text
- View/download PDF
24. History dependence in insect flight decisions during odor tracking.
- Author
-
Rich Pang, Floris van Breugel, Michael Dickinson, Jeffrey A Riffell, and Adrienne Fairhall
- Subjects
Biology (General) ,QH301-705.5 - Abstract
Natural decision-making often involves extended decision sequences in response to variable stimuli with complex structure. As an example, many animals follow odor plumes to locate food sources or mates, but turbulence breaks up the advected odor signal into intermittent filaments and puffs. This scenario provides an opportunity to ask how animals use sparse, instantaneous, and stochastic signal encounters to generate goal-oriented behavioral sequences. Here we examined the trajectories of flying fruit flies (Drosophila melanogaster) and mosquitoes (Aedes aegypti) navigating in controlled plumes of attractive odorants. While it is known that mean odor-triggered flight responses are dominated by upwind turns, individual responses are highly variable. We asked whether deviations from mean responses depended on specific features of odor encounters, and found that odor-triggered turns were slightly but significantly modulated by two features of odor encounters. First, encounters with higher concentrations triggered stronger upwind turns. Second, encounters occurring later in a sequence triggered weaker upwind turns. To contextualize the latter history dependence theoretically, we examined trajectories simulated from three normative tracking strategies. We found that neither a purely reactive strategy nor a strategy in which the tracker learned the plume centerline over time captured the observed history dependence. In contrast, "infotaxis", in which flight decisions maximized expected information gain about source location, exhibited a history dependence aligned in sign with the data, though much larger in magnitude. These findings suggest that while true plume tracking is dominated by a reactive odor response it might also involve a history-dependent modulation of responses consistent with the accumulation of information about a source over multi-encounter timescales. This suggests that short-term memory processes modulating decision sequences may play a role in natural plume tracking.
- Published
- 2018
- Full Text
- View/download PDF
25. MetaboClust: Using interactive time-series cluster analysis to relate metabolomic data with perturbed pathways.
- Author
-
Martin J Rusilowicz, Michael Dickinson, Adrian J Charlton, Simon O'Keefe, and Julie Wilson
- Subjects
Medicine ,Science - Abstract
MOTIVATION:Modern analytical techniques such as LC-MS, GC-MS and NMR are increasingly being used to study the underlying dynamics of biological systems by tracking changes in metabolite levels over time. Such techniques are capable of providing information on large numbers of metabolites simultaneously, a feature that is exploited in non-targeted studies. However, since the dynamics of specific metabolites are unlikely to be known a priori this presents an initial subjective challenge as to where the focus of the investigation should be. Whilst a number of feed-forward software tools are available for manipulation of metabolomic data, no tool centralizes on clustering and focus is typically directed by a workflow that is chosen in advance. RESULTS:We present an interactive approach to time-course analyses and a complementary implementation in a software package, MetaboClust. This is presented through the analysis of two LC-MS time-course case studies on plants (Medicago truncatula and Alopecurus myosuroides). We demonstrate a dynamic, user-centric workflow to clustering with intrinsic visual feedback at all stages of analysis. The software is used to apply data correction, generate the time-profiles, perform exploratory statistical analysis and assign tentative metabolite identifications. Clustering is used to group metabolites in an unbiased manner, allowing pathway analysis to score metabolic pathways, based on their overlap with clusters showing interesting trends.
- Published
- 2018
- Full Text
- View/download PDF
26. Improved Drought Stress Response in Alfalfa Plants Nodulated by an IAA Over-producing Rhizobium Strain
- Author
-
Roberto Defez, Anna Andreozzi, Michael Dickinson, Adrian Charlton, Luca Tadini, Paolo Pesaresi, and Carmen Bianco
- Subjects
rhizobium ,legume ,nitrogen fixation ,drought stress ,indole-3-acetic acid ,ABA ,Microbiology ,QR1-502 - Abstract
The drought–stress response in plant involves the cross-talk between abscisic acid (ABA) and other phytohormones, such as jasmonates and ethylene. The auxin indole-3-acetic acid (IAA) plays an integral part in plant adaptation to drought stress. Investigation was made to see how the main auxin IAA interacted with other plant hormones under water stress, applied through two different growth conditions (solid and hydroponic). Medicago sativa plants nodulated by the Ensifer meliloti wild type 1021 (Ms-1021) and its IAA-overproducing RD64 derivative strains (Ms-RD64) were subjected to drought stress, comparing their response. When the expression of nifH gene and the activity of the nitrogenase enzyme were measured after stress treatments, Ms-RD64 plants recorded a significantly weaker damage. These results were correlated with a lower biomass reduction, and a higher Rubisco protein level measured for the Ms-RD64-stressed plants as compared to the Ms-1021-stressed ones. It has been verified that the stress response observed for Ms-RD64-stressed plants was related to the production of greater amount of low-molecular-weight osmolytes, such as proline and pinitol, measured in these plants. For the Ms-RD64 plants the immunoblotting analysis of thylakoid membrane proteins showed that some of the photosystem proteins increased after the stress. An increased non-photochemical quenching after the stress was also observed for these plants. The reduced wilting signs observed for these plants were also connected to the significant down-regulation of the MtAA03 gene involved in the ABA biosynthesis, and with the unchanged expression of the two genes (Mt-2g006330 and Mt-8g095330) of ABA signaling. When the expression level of the ethylene-signaling genes was evaluated by qPCR analysis no significant alteration of the key positive regulators was recorded for Ms-RD64-stressed plants. Coherently, these plants accumulated 40% less ethylene as compared to Ms-1021-stressed ones. The results presented herein indicate that the variations in endogenous IAA levels, triggered by the overproduction of rhizobial IAA inside root nodules, positively affected drought stress response in nodulated alfalfa plants.
- Published
- 2017
- Full Text
- View/download PDF
27. A Plant-Feeding Nematode Indirectly Increases the Fitness of an Aphid
- Author
-
Grace A. Hoysted, Catherine J. Lilley, Katie J. Field, Michael Dickinson, Sue E. Hartley, and Peter E. Urwin
- Subjects
aboveground–belowground interactions ,aphids ,induced defenses ,jasmonic acid ,plant parasitic nematodes ,salicylic acid ,Plant culture ,SB1-1110 - Abstract
Plants suffer multiple, simultaneous assaults from above and below ground. In the laboratory, pests and/or pathogen attack are commonly studied on an individual basis. The molecular response of the plant to attack from multiple organisms and the interaction of different defense pathways is unclear. The inducible systemic responses of the potato (Solanum tuberosum L.) host plant were analyzed to characterize the plant-mediated indirect interactions between a sedentary, endoparasitic nematode (Globodera pallida), and a phloem-sucking herbivore (Myzus persicae). The reproductive success of M. persicae was greater on potato plants pre-infected with G. pallida compared to control plants. Salicylic acid (SA) increased systemically in the leaves of potato plants following nematode and aphid infection singly with a corresponding increase in expression of SA-mediated marker genes. An increase in jasmonic acid associated with aphid infection was suppressed when plants were co-infected with nematodes. Our data suggests a positive, asymmetric interaction between a sedentary endoparasitic nematode and a sap-sucking insect. The systemic response of the potato plant following infection with G. pallida indirectly influences the performance of M. persicae. This work reveals additional secondary benefits of controlling individual crop pests.
- Published
- 2017
- Full Text
- View/download PDF
28. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
- Author
-
Michael R. Bishop, Michael Dickinson, Duncan Purtill, Pere Barba, Armando Santoro, Nada Hamad, Koji Kato, Anna Sureda, Richard Greil, Catherine Thieblemont, Franck Morschhauser, Martin Janz, Ian Flinn, Werner Rabitsch, Yok-Lam Kwong, Marie J. Kersten, Monique C. Minnema, Harald Holte, Esther H.L. Chan, Joaquin Martinez-Lopez, Antonia M.S. Müller, Richard T. Maziarz, Joseph P. McGuirk, Emmanuel Bachy, Steven Le Gouill, Martin Dreyling, Hideo Harigae, David Bond, Charalambos Andreadis, Peter McSweeney, Mohamed Kharfan-Dabaja, Simon Newsome, Evgeny Degtyarev, Rakesh Awasthi, Christopher del Corral, Giovanna Andreola, Aisha Masood, Stephen J. Schuster, Ulrich Jäger, Peter Borchmann, Jason R. Westin, Hematology, Clinical Haematology, and CCA - Cancer Treatment and Quality of Life
- Subjects
Adult ,Male ,Salvage Therapy ,Cancer Research ,Receptors, Chimeric Antigen ,Hematopoietic Stem Cell Transplantation ,Receptors, Antigen, T-Cell ,General Medicine ,Middle Aged ,Combined Modality Therapy ,Immunotherapy, Adoptive ,Transplantation, Autologous ,Progression-Free Survival ,Antineoplastic Agents, Immunological ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Female ,Lymphoma, Large B-Cell, Diffuse ,Aged - Abstract
BACKGROUND: Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an anti-CD19 chimeric antigen receptor T-cell therapy approved for diffuse large B-cell lymphoma after at least two treatment lines. METHODS: We conducted an international phase 3 trial involving patients with aggressive lymphoma that was refractory to or progressing within 12 months after first-line therapy. Patients were randomly assigned to receive tisagenlecleucel with optional bridging therapy (tisagenlecleucel group) or salvage chemotherapy and autologous hematopoietic stem-cell transplantation (HSCT) (standard-care group). The primary end point was event-free survival, defined as the time from randomization to stable or progressive disease at or after the week 12 assessment or death. Crossover to receive tisagenlecleucel was allowed if a defined event occurred at or after the week 12 assessment. Other end points included response and safety. RESULTS: A total of 322 patients underwent randomization. At baseline, the percentage of patients with high-grade lymphomas was higher in the tisagenlecleucel group than in the standard-care group (24.1% vs. 16.9%), as was the percentage with an International Prognostic Index score (range, 0 to 5, with higher scores indicating a worse prognosis) of 2 or higher (65.4% vs. 57.5%). A total of 95.7% of the patients in the tisagenlecleucel group received tisagenlecleucel; 32.5% of the patients in the standard-care group received autologous HSCT. The median time from leukapheresis to tisagenlecleucel infusion was 52 days. A total of 25.9% of the patients in the tisagenlecleucel group had lymphoma progression at week 6, as compared with 13.8% of those in the standard-care group. The median event-free survival in both groups was 3.0 months (hazard ratio for event or death in the tisagenlecleucel group, 1.07; 95% confidence interval, 0.82 to 1.40; P = 0.61). A response occurred in 46.3% of the patients in the tisagenlecleucel group and in 42.5% in the standard-care group. Ten patients in the tisagenlecleucel group and 13 in the standard-care group died from adverse events. CONCLUSIONS: Tisagenlecleucel was not superior to standard salvage therapy in this trial. Additional studies are needed to assess which patients may obtain the most benefit from each approach. (Funded by Novartis; BELINDA ClinicalTrials.gov number, NCT03570892.).
- Published
- 2022
- Full Text
- View/download PDF
29. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
- Author
-
Gilles Salles, Stephen J. Schuster, Martin Dreyling, Luca Fischer, John Kuruvilla, Piers E. M. Patten, Bastian von Tresckow, Sonali M. Smith, Ana Jiménez-Ubieto, Keith L. Davis, Carla Anjos, Jufen Chu, Jie Zhang, Chiara Lobetti Bodoni, Catherine Thieblemont, Nathan H. Fowler, Michael Dickinson, Joaquin Martínez-López, Yucai Wang, and Brian K. Link
- Subjects
Receptors, Antigen, T-Cell ,Medizin ,Humans ,Hematology ,Neoplasm Recurrence, Local ,Lymphoma, Follicular ,Retrospective Studies - Abstract
The ELARA trial indicates tisagenlecleucel (tisa-cel) is an effective anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory follicular lymphoma (r/r FL). As ELARA is a single-arm trial, this study compares tisa-cel outcomes from the ELARA trial with usual care from a real-world cohort. ELARA enrolled 98 patients as of 29 March 2021 (median follow-up: 15 months from enrollment). Usual care data were obtained from ReCORD-FL, a global retrospective study of patients with r/r FL, who met similar eligibility criteria to ELARA. With a data cutoff date of 31 December 2020, 187 patients with ≥2 preceding treatment lines were included in the ReCORD-FL (median follow-up: 57 months from third-line) study. An indirect treatment comparison was performed for 97 patients from the ELARA trial and 143 patients from the ReCORD-FL study with no missing data on baseline factors. The line of therapy for which outcomes were assessed was selected or matched between cohorts using propensity score modeling. After baseline factor adjustment via weighting by odds, complete response rate (CRR; 95% confidence interval) was 69.1% (59.8%-78.3%) for tisa-cel vs. 37.3% (26.4%-48.3%) for usual care; overall response rate was 85.6% (78.7%-92.5%) vs. 63.6% (52.5%-74.7%). Kaplan-Meier probability of being progression/event-free at 12 months was 70.5% (61.4%-79.7%) for tisa-cel vs. 51.9% (40.6%-63.3%) for usual care, with hazard ratio (HR)=0.60 (0.34-0.86); 12-month overall survival was 96.6% (92.9%-100%) vs. 71.7% (61.2%-82.2%), with HR=0.2 (0.02-0.38). In conclusion, tisa-cel was associated with a 1.9-fold higher complete response rate and a 1.4-fold higher rate of being progression or event free at 12 months vs usual care, as well as a death risk reduction of 80%. The findings provide additional evidence on the benefit of tisa-cel in patients with r/r FL after ≥2 treatment lines. This trial was registered at www.clinicaltrials.gov as NCT03568461
- Published
- 2022
30. Overview of Histone Deacetylase Inhibitors in Haematological Malignancies
- Author
-
H. Miles Prince, Simon Harrison, Mark J. Bishton, Ricky W. Johnstone, and Michael Dickinson
- Subjects
Histone deacetylase inhibitors ,Clinical studies ,Haematology ,Medicine ,Pharmacy and materia medica ,RS1-441 - Abstract
Histone deacetylase inhibitors (HDACi) can induce hyperacetylation of both histone and non-histone target resulting in epigenetic reprogramming and altered activity, stability and localisation of non-histone proteins to ultimately mediate diverse biological effects on cancer cells and their microenvironment. Clinical trials have demonstrated single agent HDACi to have activity in hematological malignancies, in particular T-cell lymphoma and Hodgkin lymphoma. Combination strategies with standard therapies based on pre-clinical data are being employed with significant success due to their excellent side effect profile. Correlative studies will provide valuable information on the sub-groups of patients more likely to respond or be resistant to HDACi therapy, while long-term monitoring for toxicities is also needed.
- Published
- 2010
- Full Text
- View/download PDF
31. Rehabilitation in patients with lymphoma: An overview of Systematic Reviews
- Author
-
Michael Dickinson, Fary Khan, Bhasker Amatya, and Thomas E Lew
- Subjects
Sleep disorder ,medicine.medical_specialty ,Modalities ,Rehabilitation ,critical appraisal ,business.industry ,medicine.medical_treatment ,Physical Therapy, Sports Therapy and Rehabilitation ,lymphoma ,General Medicine ,Grey literature ,RM1-950 ,medicine.disease ,rehabilitation ,Critical appraisal ,Systematic review ,Data extraction ,Quality of life ,systematic review ,medicine ,Physical therapy ,Quality of Life ,Humans ,Therapeutics. Pharmacology ,business - Abstract
Objective: To evaluate existing evidence from published systematic reviews for the effectiveness of rehabilitation interventions in patients with lymphoma. Data sources: A comprehensive literature search was conducted using medical/health science databases up to 1 October 2020. Bibliographies of pertinent articles, journals and grey literature were searched. Data extraction and synthesis: Two reviewers independently selected and reviewed potential reviews for methodological quality and graded the quality of evidence for outcomes using validated tools. Any discrepancies were resolved by final group consensus. Results: Twelve systematic reviews (n = 101 studies, 87,132 patients with lymphoma) evaluated 3 broad categories of rehabilitation interventions (physical modalities, nutrition and complementary medicine). Most reviews were of moderate-to-low methodological quality. The findings suggest: moderate-quality evidence for exercise programmes for improved fatigue and sleep disturbance; low-quality evidence for exercise therapy alone and qigong/tai chi for improved symptoms and overall quality of life, and an inverse association between sunlight/ultraviolet radiation exposure and incidence of non-Hodgkin’s lymphoma; and very low-quality evidence for beneficial effects of yoga for sleep disturbances. Association between physical activity and lymphoma risk is indistinct. Conclusion: Despite a range of rehabilitation modalities used for patients with lymphoma, high-quality evidence for many is sparse. Beneficial effects of exercise programmes were noted for fatigue, psychological symptoms and quality of life. More research with robust study design is required to determine the effective rehabilitation approaches.
- Published
- 2021
32. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
- Author
-
Nathan Hale Fowler, Michael Dickinson, Martin Dreyling, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie José Kersten, Charalambos Andreadis, Peter A. Riedell, P. Joy Ho, José Antonio Pérez-Simón, Andy I. Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andrés José María Ferreri, Takanori Teshima, Piers E. M. Patten, Joseph P. McGuirk, Andreas L. Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Aiesha Zia, Rakesh Awasthi, Aisha Masood, Oezlem Anak, Stephen J. Schuster, Catherine Thieblemont, Fowler N.H., Dickinson M., Dreyling M., Martinez-Lopez J., Kolstad A., Butler J., Ghosh M., Popplewell L., Chavez J.C., Bachy E., Kato K., Harigae H., Kersten M.J., Andreadis C., Riedell P.A., Ho P.J., Perez-Simon J.A., Chen A.I., Nastoupil L.J., von Tresckow B., Ferreri A.J.M., Teshima T., Patten P.E.M., McGuirk J.P., Petzer A.L., Offner F., Viardot A., Zinzani P.L., Malladi R., Zia A., Awasthi R., Masood A., Anak O., Schuster S.J., Thieblemont C., Novartis Foundation for Sustainable Development, Clinical Haematology, AII - Cancer immunology, CCA - Cancer biology and immunology, and CCA - Cancer Treatment and Quality of Life
- Subjects
Adult ,B-cell lymphoma ,Antigens, CD19 ,Medizin ,Receptors, Antigen, T-Cell ,Pilot Projects ,Cancer immunotherapy ,General Medicine ,Immunotherapy, Adoptive ,General Biochemistry, Genetics and Molecular Biology ,Phase II trials ,Humans ,B-cell lymphoma, Tisagenlecleucel, T cell therapy ,Lymphoma, Follicular - Abstract
Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor-T cell therapy with clinically meaningful outcomes demonstrated in patients with relapsed/refractory (r/r) B-cell lymphoma. In a previous pilot study of tisagenlecleucel in r/r follicular lymphoma (FL), 71% of patients achieved a complete response (CR). Here we report the primary, prespecified interim analysis of the ELARA phase 2 multinational trial of tisagenlecleucel in adults with r/r FL after two or more treatment lines or who relapsed after autologous stem cell transplant (no. NCT03568461). The primary endpoint was CR rate (CRR). Secondary endpoints included overall response rate (ORR), duration of response, progression-free survival, overall survival, pharmacokinetics and safety. As of 29 March 2021, 97/98 enrolled patients received tisagenlecleucel (median follow-up, 16.59 months; interquartile range, 13.8–20.21). The primary endpoint was met. In the efficacy set (n = 94), CRR was 69.1% (95% confidence interval, 58.8–78.3) and ORR 86.2% (95% confidence interval, 77.5–92.4). Within 8 weeks of infusion, rates of cytokine release syndrome were 48.5% (grade ≥3, 0%), neurological events 37.1% (grade ≥3, 3%) and immune effector cell-associated neurotoxicity syndrome (ICANS) 4.1% (grade ≥3, 1%) in the safety set (n = 97), with no treatment-related deaths. Tisagenlecleucel is safe and effective in extensively pretreated r/r FL, including in high-risk patients., The study was sponsored and designed by Novartis Pharmaceuticals Corporation and was approved by the IRB at each participating institution.
- Published
- 2021
- Full Text
- View/download PDF
33. Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic
- Author
-
Michael Dickinson, Richard Doocey, Maya Latimer, Cindy Lee, Simon D. J. Gibbs, Joel Wight, Pietro R Di Ciaccio, Matthew Ku, Robin Gasiorowski, Shane A Gangatharan, Hang Quach, Hui Peng Lee, Stephen P. Mulligan, Robert Weinkove, Leanne Berkhahn, Chan Yoon Cheah, Mark N. Polizzotto, Simon J. Harrison, Andrew Spencer, Constantine S. Tam, Phoebe Joy Ho, Tasman Armytage, Anna Johnston, Scott Chapman, Nicholas Webber, Belinda A. Campbell, Henry Miles Prince, Tara Cochrane, Georgia McCaughan, Nada Hamad, Judith Trotman, Greg Hapgood, and Gareth P. Gregory
- Subjects
medicine.medical_specialty ,Consensus ,Lymphoma ,Pneumonia, Viral ,Telehealth ,Comorbidity ,030204 cardiovascular system & hematology ,Risk Assessment ,03 medical and health sciences ,Betacoronavirus ,0302 clinical medicine ,Pharmacotherapy ,Drug Therapy ,Health care ,Pandemic ,medicine ,Internal Medicine ,Infection control ,Humans ,030212 general & internal medicine ,Intensive care medicine ,Pandemics ,Salvage Therapy ,Infection Control ,business.industry ,SARS-CoV-2 ,Australia ,COVID-19 ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,Coronavirus ,Clinical research ,Practice Guidelines as Topic ,Guideline Adherence ,business ,Risk assessment ,Coronavirus Infections ,Multiple Myeloma ,New Zealand ,Stem Cell Transplantation - Abstract
The COVID-19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known to cause disproportionately severe disease in patients with cancer, and patients with lymphoma, myeloma and chronic lymphocytic leukaemia are likely to be at particular risk of severe disease related to COVID-19. This statement has been developed by consensus among authors from Australia and New Zealand. We aim to provide supportive guidance to clinicians making individual patient decisions during the COVID-19 pandemic, in particular during periods that access to healthcare resources may be limited. General recommendations include those to minimise patient exposure to COVID-19, including the use of telehealth, avoidance of non-essential visits and minimisation of time spent by patients in infusion suites and other clinical areas. This statement also provides recommendations where appropriate in assessing indications for therapy, reducing therapy-associated immunosuppression and reducing healthcare utilisation in patients with specific haematological malignancies during the COVID-19 pandemic. Specific decisions regarding therapy of haematological malignancies will need to be individualised, based on disease risk, risks of immunosuppression, rates of community transmission of COVID-19 and available local healthcare resources.
- Published
- 2020
34. Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS
- Author
-
Tim M. Crozier, Greg Corboy, Michael Dickinson, Piers Blombery, Jake Shortt, Beena Kumar, Stephen Opat, Costas K. Yannakou, Lev Kats, H. Miles Prince, Jonathan Wong, and Gareth P. Gregory
- Subjects
Oncology ,medicine.medical_specialty ,Hematology ,business.industry ,lcsh:RC633-647.5 ,T cell ,Azacitidine ,Complete remission ,Case Report ,lcsh:Diseases of the blood and blood-forming organs ,medicine.disease ,Lymphoma ,medicine.anatomical_structure ,Refractory ,Internal medicine ,Mutation (genetic algorithm) ,medicine ,business ,medicine.drug - Published
- 2019
- Full Text
- View/download PDF
35. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia
- Author
-
Uwe Platzbecker, Maria Socorro O Portella, Honar Cherif, Moshe Mittelman, Michael Dickinson, Jeea Choi, Amit Verma, Pierre Fenaux, Pedro Marques Ramos, and Paul Burgess
- Subjects
Adult ,Male ,medicine.medical_specialty ,Clinical Trials and Observations ,Immunology ,Azacitidine ,Eltrombopag ,Platelet Transfusion ,Placebo ,Biochemistry ,Benzoates ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Double-Blind Method ,Risk Factors ,Internal medicine ,hemic and lymphatic diseases ,medicine ,Clinical endpoint ,Humans ,Adverse effect ,Aged ,Aged, 80 and over ,business.industry ,Myelodysplastic syndromes ,Cell Biology ,Hematology ,Middle Aged ,medicine.disease ,Thrombocytopenia ,Hydrazines ,chemistry ,International Prognostic Scoring System ,030220 oncology & carcinogenesis ,Myelodysplastic Syndromes ,Pyrazoles ,Female ,business ,Febrile neutropenia ,030215 immunology ,medicine.drug - Abstract
Azacitidine treatment of myelodysplastic syndromes (MDSs) generally exacerbates thrombocytopenia during the first treatment cycles. A Study of Eltrombopag in Myelodysplastic Syndromes Receiving Azacitidine (SUPPORT), a phase 3, randomized, double-blind, placebo-controlled study, investigated the platelet supportive effects of eltrombopag given concomitantly with azacitidine. International Prognostic Scoring System intermediate-1, intermediate-2, or high-risk MDS patients with baseline platelets
- Published
- 2018
36. NMR Metabolomics Defining Genetic Variation in Pea Seed Metabolites
- Author
-
Adrian J. Charlton, Michael Dickinson, Giampaolo Venditti, Noel Ellis, Zoltán Szabó, James Donarski, Jitender Cheema, Claire Domoney, György B. Kiss, Chie Hattori, and Péter Kaló
- Subjects
0106 biological sciences ,0301 basic medicine ,Metabolite ,pea ,metabolite ,Genomics ,Plant Science ,Biology ,lcsh:Plant culture ,01 natural sciences ,Genetic analysis ,03 medical and health sciences ,chemistry.chemical_compound ,Metabolomics ,Gene mapping ,Genetic variation ,Metabolome ,genetic map ,lcsh:SB1-1110 ,Original Research ,2. Zero hunger ,Genetics ,food and beverages ,nuclear magnetic resonance ,030104 developmental biology ,chemistry ,Genetic marker ,genetic variation ,seed ,010606 plant biology & botany - Abstract
Nuclear magnetic resonance (NMR) spectroscopy profiling was used to provide an unbiased assessment of changes to the metabolite composition of seeds and to define genetic variation for a range of pea seed metabolites. Mature seeds from recombinant inbred lines, derived from three mapping populations for which there is substantial genetic marker linkage information, were grown in two environments/years and analyzed by non-targeted NMR. Adaptive binning of the NMR metabolite data, followed by analysis of quantitative variation among lines for individual bins, identified the main genomic regions determining this metabolic variability and the variability for selected compounds was investigated. Analysis by t-tests identified a set of bins with highly significant associations to genetic map regions, based on probability (p) values that were appreciably lower than those determined for randomized data. The correlation between bins showing high mean absolute deviation and those showing low p-values for marker association provided an indication of the extent to which the genetics of bin variation might be explained by one or a few loci. Variation in compounds related to aromatic amino acids, branched-chain amino acids, sucrose-derived metabolites, secondary metabolites and some unidentified compounds was associated with one or more genetic loci. The combined analysis shows that there are multiple loci throughout the genome that together impact on the abundance of many compounds through a network of interactions, where individual loci may affect more than one compound and vice versa. This work therefore provides a framework for the genetic analysis of the seed metabolome, and the use of genetic marker data in the breeding and selection of seeds for specific seed quality traits and compounds that have high commercial value.
- Published
- 2018
- Full Text
- View/download PDF
37. Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy
- Author
-
Lucy C. Fox, Michael Dickinson, Stephen Lade, Costas K. Yannakou, Henry Miles Prince, Belinda A. Campbell, and Georgina L Ryland
- Subjects
0301 basic medicine ,Case Report ,primary cutaneous diffuse large B-cell lymphoma, leg type ,Catalysis ,Inorganic Chemistry ,Pathogenesis ,lcsh:Chemistry ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Chemoimmunotherapy ,ibrutinib ,medicine ,Primary Cutaneous Diffuse Large B-Cell Lymphoma ,Bruton's tyrosine kinase ,Physical and Theoretical Chemistry ,Molecular Biology ,lcsh:QH301-705.5 ,Spectroscopy ,biology ,Organic Chemistry ,General Medicine ,medicine.disease ,NFKBIE ,Computer Science Applications ,Lymphoma ,030104 developmental biology ,chemistry ,lcsh:Biology (General) ,lcsh:QD1-999 ,030220 oncology & carcinogenesis ,Ibrutinib ,Cancer research ,biology.protein ,IRF8 - Abstract
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) is one of the well-recognized extranodal lymphomas commonly addicted to the B-cell receptor-MYD88 superpathway. We aimed to describe the genomic changes in a patient who progressed through treatment with ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor. An 80-year-old woman presented with multiply relapsed PCDLBCL-LT after multiple lines of chemoimmunotherapy and radiotherapy. Pre-treatment testing of the localized cutaneous tumor lesion on a lymphoid amplicon panel demonstrated an MYD88 p.L265P mutation. Ibrutinib therapy was subsequently commenced, resulting in complete resolution of the skin disease. Despite an ongoing skin response, the patient developed progressive nodal disease at two months. Genomic analysis of the cutaneous tumor sample at baseline was compared to that of the inguinal lymph node upon progression, and revealed the acquisition of multiple genomic changes. These included several aberrations expected to bypass BTK inhibition, including two CARD11-activating mutations, and a deleterious mutation in the nuclear factor kappa B (NF-κB) negative regulator, NFKBIE. In addition, an IgH-IRF8 translocation was detected (which brings the IRF8 transcription factor under control of the immunoglobulin heavy chain locus), representing a third plausible mechanism contributing to ibrutinib resistance. Several copy-number changes occurred in both samples, including an amplification of 18q, which encodes the anti-apoptotic protein BCL2. We describe the first case of novel genomic changes of PCDLBCL-LT that occurred while on ibrutinib, providing important mechanistic insights into both pathogenesis and drug resistance.
- Published
- 2018
38. Improved Drought Stress Response in Alfalfa Plants Nodulated by an IAA Over-producing Rhizobium Strain
- Author
-
Anna Andreozzi, Paolo Pesaresi, Adrian J. Charlton, Michael Dickinson, Luca Tadini, Carmen Bianco, and Roberto Defez
- Subjects
0106 biological sciences ,0301 basic medicine ,Microbiology (medical) ,Root nodule ,lcsh:QR1-502 ,Photosynthesis ,01 natural sciences ,Microbiology ,lcsh:Microbiology ,03 medical and health sciences ,chemistry.chemical_compound ,rhizobium ,Auxin ,ethylene ,Abscisic acid ,Original Research ,2. Zero hunger ,chemistry.chemical_classification ,photosynthesis ,biology ,IAA ,RuBisCO ,fungi ,drought stress ,Wilting ,food and beverages ,legume ,Horticulture ,030104 developmental biology ,chemistry ,ABA ,Osmolyte ,nitrogen fixation ,biology.protein ,indole-3-acetic acid ,Indole-3-acetic acid ,010606 plant biology & botany - Abstract
The drought-stress response in plant involves the cross-talk between abscisic acid (ABA) and other phytohormones, such as jasmonates and ethylene. The auxin indole-3-acetic acid (IAA) plays an integral part in plant adaptation to drought stress. Investigation was made to see how the main auxin IAA interacted with other plant hormones under water stress, applied through two different growth conditions (solid and hydroponic). Medicago sativa plants nodulated by the Ensifer meliloti wild type 1021 (Ms-1021) and its IAA-overproducing RD64 derivative strains (Ms-RD64) were subjected to drought stress, comparing their response. When the expression of nifH gene and the activity of the nitrogenase enzyme were measured after stress treatments, Ms-RD64 plants recorded a significantly weaker damage. These results were correlated with a lower biomass reduction, and a higher Rubisco protein level measured for the Ms-RD64-stressed plants as compared to the Ms-1021-stressed ones. It has been verified that the stress response observed for Ms-RD64-stressed plants was related to the production of greater amount of low-molecular-weight osmolytes, such as proline and pinitol, measured in these plants. For the Ms-RD64 plants the immunoblotting analysis of thylakoid membrane proteins showed that some of the photosystem proteins increased after the stress. An increased non-photochemical quenching after the stress was also observed for these plants. The reduced wilting signs observed for these plants were also connected to the significant down-regulation of the MtAA03 gene involved in the ABA biosynthesis, and with the unchanged expression of the two genes (Mt-2g006330 and Mt-8g095330) of ABA signaling. When the expression level of the ethylene-signaling genes was evaluated by qPCR analysis no significant alteration of the key positive regulators was recorded for Ms-RD64-stressed plants. Coherently, these plants accumulated 40% less ethylene as compared to Ms-1021-stressed ones. The results presented herein indicate that the variations in endogenous IAA levels, triggered by the overproduction of rhizobial IAA inside root nodules, positively affected drought stress response in nodulated alfalfa plants.
- Published
- 2017
- Full Text
- View/download PDF
39. Acute myeloid leukemia patients’ clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts
- Author
-
Michael Dickinson, Gong Chen, W. Venus So, Lin-Chi Chen, Lori Jukofsky, Giovanni Martinelli, Je-Hwan Lee, Karen W.L. Yee, Mark Drummond, Ruediger Rueger, Bernhard Reis, Sarit Assouline, Steven Blotner, Margaret Kasner, Sung-Soo Yoon, Michel Theron, Gwen Nichols, Steven A. Middleton, William E. Pierceall, Kevin R. Kelly, Norbert Vey, Karen Seiter, Hua Zhong, Maneja Hashemyan, Reis, Bernhard, Jukofsky, Lori, Chen, Gong, Martinelli, Giovanni, Zhong, Hua, Venus So, W., Dickinson, Michael J., Drummond, Mark, Assouline, Sarit, Hashemyan, Maneja, Theron, Michel, Blotner, Steven, Lee, Je-Hwan, Kasner, Margaret, Yoon, Sung-Soo, Rueger, Ruediger, Seiter, Karen, Middleton, Steven A., Kelly, Kevin R., Vey, Norbert, Yee, Karen, Nichols, Gwen, Chen, Lin-Chi, and Pierceall, William E
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Myeloid ,Idasanutlin ,CD34 ,Bioinformatics ,Flow cytometry ,03 medical and health sciences ,0302 clinical medicine ,AML ,Internal medicine ,medicine ,Online Only Articles ,neoplasms ,Complementary diagnostic ,biology ,medicine.diagnostic_test ,business.industry ,Myeloid leukemia ,Hematology ,medicine.disease ,MDM2 antagonism ,Clinical trial ,Leukemia ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,biology.protein ,Biomarker (medicine) ,Mdm2 ,business - Abstract
In translational research described, we investigated biomarker expression by flow cytometry for MDM2 antagonist clinical response association in relapsed/refractory AML patients treated with idasanutlin-based therapy (Clinicaltrials.gov identifier: {"type":"clinical-trial","attrs":{"text":"NCT01773408","term_id":"NCT01773408"}}NCT01773408). As MDM2 targets p53 for ubiquination/degradation, higher levels of MDM2 protein expression would be consistent with a mechanism of increased malignant potential by decreased p53 activity. We hypothesized that this comprises a mechanism for oncogene addiction whereby the cell is uniquely sensitive to enhanced p53 activity by MDM2 antagonism through reliance on this pathway. Flow cytometry assessment of MDM2 protein expression in leukemic blasts (CD45dim or CD45dim/CD34+) is established in both a proof of principle set comprising initial trial segments, and then validated in a trial segment comprising patients treated with a clinically optimized idasanutlin formulation. Upon TP53 WT patient subset analyses, we show that flow cytometry assessments add predictive/prognostic value to negative predictive value conferred by TP53 mutational status. Additionally, we propose that such continuous variable measurements are consistent with FDA guidance for the development of complementary diagnostics. These flow cytometry assessments will be monitored in upcoming AML clinical trials for predictive diagnostic potential.
- Published
- 2016
40. Overview of Histone Deacetylase Inhibitors in Haematological Malignancies
- Author
-
Michael Dickinson, H. Miles Prince, Simon J. Harrison, Mark Bishton, and Ricky W. Johnstone
- Subjects
medicine.medical_specialty ,Side effect ,Pharmaceutical Science ,lcsh:Medicine ,lcsh:RS1-441 ,Review ,Bioinformatics ,lcsh:Pharmacy and materia medica ,Internal medicine ,Histone deacetylase inhibitors ,Drug Discovery ,medicine ,Hematology ,biology ,lcsh:R ,medicine.disease ,Lymphoma ,Clinical trial ,Histone ,Cancer cell ,biology.protein ,Molecular Medicine ,Histone deacetylase ,Reprogramming ,Clinical studies ,Haematology - Abstract
Histone deacetylase inhibitors (HDACi) can induce hyperacetylation of both histone and non-histone target resulting in epigenetic reprogramming and altered activity, stability and localisation of non-histone proteins to ultimately mediate diverse biological effects on cancer cells and their microenvironment. Clinical trials have demonstrated single agent HDACi to have activity in hematological malignancies, in particular T-cell lymphoma and Hodgkin lymphoma. Combination strategies with standard therapies based on pre-clinical data are being employed with significant success due to their excellent side effect profile. Correlative studies will provide valuable information on the sub-groups of patients more likely to respond or be resistant to HDACi therapy, while long-term monitoring for toxicities is also needed.
- Published
- 2010
41. Development of a biomimetic robotic bear: Or is a bare bear bearable?
- Author
-
Michael Dickinson and Peter Turner
- Subjects
Engineering ,business.industry ,Human–computer interaction ,High mass ,Robot ,Artificial intelligence ,Biomimetics ,Motion control ,business ,Robot motion - Abstract
This paper presents the issues encountered in the development of a robot based on the biometric influence of a bear. One of the main aims of this research was to explore the possibilities of a robot, which could move between the different styles of motion. The bear offers a unique example of an animal with high mass and bulk, which can move between being a quadruped and a biped. Our earlier research had explored the development of a robotic dog. A quadruped robot design, suitable for use as a player in the RoboCup Four Legged League, which used the parameters of the existing Sony Aibo robot as a starting point. The outcomes of this research have been discussed in papers by Chalup and Lawrence. The current research has extended the previous platform development and reset the objective to a robot with both bipedal and quadrupedal motion possibilities. The original objectives of developing a high quality design with enhanced research programming possibilities, which also coveys a positive and engaging image of Science and Engineering through its form, were maintained. This is specially so, when considering the robot's ability to create interest in the general public, who will view the robot from a perspective outside of discipline specific interests. The introduction presents the biological inspiration for the current design, including the preparation and material production considerations. This is followed by a discussion of specific features of the robotic bear design, which has been given the name HyKim, followed by a conclusion.
- Published
- 2009
42. HyKim - Development of a robot bear: Bringing the strength and robustness of a bear's biomimetic features to a robot
- Author
-
Peter Turner and Michael Dickinson
- Subjects
Engineering ,Social robot ,business.industry ,Control engineering ,Robotics ,Modularity ,Human–computer interaction ,Robot ,AIBO ,Artificial intelligence ,Open architecture ,Architecture ,business ,Humanoid robot - Abstract
There are many commercially available robots that display biomimetic influences. Sony's Aibo and DasaRobot's Genibo are two examples where robot dog designs have drawn from nature. Aldebaran's Nao and Hanson Robotics' Zeno are examples of humanoids robots that have drawn influences from the human body. This paper presents the design of an autonomous 21 degree of freedom (DOF) robot bear, named HyKim and discusses the relevant biomimetic influences. After discussing the motivation for creating a robot bear, the biomimetic principles that were applied to the mechanical design, to ensure the resulting robot was dasiabear-likepsila, are presented. The design of the computer and electronic architecture was based on four essential design criteria - open architecture, performance, modularity and reliability. How these criteria were met is then presented, followed by a discussion on future research projects that will be based on or include HyKim. Finally a conclusion summarising the design is presented.
- Published
- 2009
43. An evaluation of the stimulants and impediments to innovation within PFI/PPP projects
- Author
-
David Eaton, Rıfat Akbiyikli, and Michael Dickinson
- Subjects
Engineering ,Process management ,General Computer Science ,business.industry ,Building and Construction ,built_and_human_env ,Public–private partnership ,Identification (information) ,Procurement ,Control and Systems Engineering ,Architecture ,Private finance initiative ,TH ,Procurement process ,Operations management ,business ,Constraint (mathematics) ,Civil and Structural Engineering - Abstract
This paper identifies the theoretical stimulants and impediments associated with the implementation of PFI/PPP (Private Finance Initiative/Public Private Partnership)projects. A current defect of this procurement approach is the unintentional constraint upon the innovations incorporated into the development of PFI projects. A critical evaluation of the published literature has been utilized to synthesize a theoretical model. The paper proposes a theoretical model for the identification of potential innovation stimulants and impediments within this type of procurement. This theoretical model is then utilised to evaluate four previously completed PFI projects. These project case‐studies have been examined in detail. The evaluation demonstrates how ineffective current procedures are. The application of this model before project letting could eliminate unintentional constraints and stimulate improved innovation within the process.The implementation of the model could improve the successful delivery of innovation within the entire PFI/PPP procurement process.
- Published
- 2006
44. The influence of partnering and procurement on subcontractor involvement and innovation.
- Author
-
Per Erik Eriksson, Michael Dickinson, and Malik M.A. Khalfan
- Subjects
INDUSTRIAL procurement ,SUBCONTRACTORS ,LONGITUDINAL method ,FACTORY design & construction ,PHARMACEUTICAL industry - Abstract
Purpose - The aim of this paper is to investigate how a client's cooperative procurement procedures influence subcontractor involvement, value creation, and innovation in the construction of complex facilities. Design/methodology/approach - Empirical data were collected through interviews, surveys and participation in workshops during a longitudinal action research case study. The case project was located in Sweden and concerned the construction of plant facilities for manufacturing of pharmaceutical products. Findings - The case study findings reveal that the client's procurement procedures affect the level of subcontractor involvement and integration, but that this does not necessarily result in increased subcontractor value creation and innovation in the construction process. Research limitations/implications - Since the empirical results are based on data collected from only one case project, the possibilities for generalisations are limited. Practical implications - Clients' procurement procedures heavily affect subcontractor involvement, but in order to increase subcontractor contributions to innovation and value creation the actors should adopt a long-term perspective and actively work to establish an innovation-friendly climate. Originality/value - This paper focuses on the often-neglected importance of subcontractors and their contributions to innovation and value creation. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
45. Favorable Outcomes from Allogeneic and Autologous Stem Cell Transplantation for Patients with Transformed Nonfollicular Indolent Lymphoma
- Author
-
Jean F. Larouche, Rena Buckstein, Neil Chua, David MacDonald, John Kuruvilla, Anupkumar George, Dennis A. Carney, Michael Dickinson, John F. Seymour, Cynthia L. Toze, Kerry J. Savage, Douglas A. Stewart, Félix Couture, Tony Panzarella, Mitchell Sabloff, Anargyros Xenocostas, Christina R. Lee, Diego Villa, Joseph M. Connors, Ronan Foley, Sandra Cohen, and Michael Crump
- Subjects
medicine.medical_specialty ,Autologous transplant ,Chronic lymphocytic leukemia ,medicine.medical_treatment ,Follicular lymphoma ,Hematopoietic stem cell transplantation ,Gastroenterology ,Lymphoplasmacytic Lymphoma ,Autologous stem-cell transplantation ,immune system diseases ,Internal medicine ,hemic and lymphatic diseases ,medicine ,Survival rate ,Transplantation ,business.industry ,Hematology ,medicine.disease ,Allogeneic transplant ,Surgery ,Lymphoma ,Transformed lymphoma ,surgical procedures, operative ,business ,Rituximab ,therapeutics ,human activities - Abstract
The role of allogeneic (allo-) and autologous stem cell transplantation (auto-SCT) in the management of patients with transformed indolent nonfollicular non-Hodgkin lymphoma is unknown. This is a multicenter, retrospective cohort study of patients with biopsy-proven indolent B cell nonfollicular non-Hodgkin lymphoma and simultaneous or subsequent biopsy-proven aggressive histology transformation who were treated with allo-SCT or auto-SCT between 1996 and 2013. All patients received myeloablative conditioning regimens. Outcomes were compared with a cohort of 246 patients with transformed follicular lymphoma who also underwent allo-SCT (n = 47) or auto-SCT (n = 199) across the same institutions and time frame. Thirty-four patients were identified with the following underlying indolent histologies: 15 (44%) marginal zone lymphoma, 11 (32%) chronic lymphocytic leukemia, 6 (18%) small lymphocytic lymphoma, and 2 (6%) lymphoplasmacytic lymphoma. Patients received various anthracycline or platinum-containing chemotherapy regimens for transformation, incorporating rituximab in 25 (74%). Twelve (35%) subsequently underwent allo-SCT, whereas 33 (65%) underwent auto-SCT. The 3-year overall survival rate after transplantation was 67% (allo-SCT 54%, auto-SCT 74%), and 3-year progression-free survival rate was 49% (allo-SCT 40%, auto-SCT 54%). The 3-year nonrelapse mortality rate was 14% (allo-SCT 15%, auto-SCT 7%). Transplant-related mortality at 100 days was 17% for allo-SCT and 0% for auto-SCT. Adjusted for type of stem cell transplantation, 3-year overall survival, progression-free survival, and nonrelapse mortality rates were similar to those of patients with transformed follicular lymphoma receiving allo-SCT and auto-SCT (P = .38, P = .69, and P = .54, respectively). Allo-SCT and auto-SCT may be reasonable treatments for selected patients with transformed nonfollicular indolent lymphoma, although medium-term outcomes and toxicity appear to be more favorable with auto-SCT.
- Full Text
- View/download PDF
46. Generalized regressive motion: a visual cue to collision.
- Author
-
Krzysztof Chalupka, Michael Dickinson, and Pietro Perona
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.